tiprankstipranks
Enanta price target lowered to $18 from $27 at H.C. Wainwright
The Fly

Enanta price target lowered to $18 from $27 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Enanta (ENTA) to $18 from $27 and keeps a Buy rating on the shares. Zelicapavir successfully met the virology endpoint of RSVPEDs, a Phase 2 placebo-controlled study of zelicapavir focused on pediatric patients aged 28 days to 36 months with RSV in both hospitalized and nonhospitalized settings, but the firm has “several concerns” on zelicapavir’s ability in RSV symptom reduction, the analyst tells investors. Following the report of the top-line dataset from the trial, the firm is reducing its assumed probability of success for zelicapavir in RSV to 50% from 60%.

Don't Miss Our Christmas Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App